We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
Read MoreHide Full Article
bluebird Inc. (BLUE - Free Report) announced new data from ongoing phase III studies onits investigational betibeglogene autotemcel (formerly LentiGlobin for β-thalassemia gene therapy). The data showed that pediatric, adolescent and adult patients with a range of genotypes of transfusion-dependent β-thalassemia (TDT) achieved and maintained transfusion independence with hemoglobin (Hb) levels that are nearnormal.
TDT is a severe genetic disease caused by mutations in the β-globin gene that results in significantly reduced or absent adult hemoglobin (HbA).
A total of 60 pediatric, adolescent and adult patients across genotypes of TDT were treated with betibeglogenein the phase I/IINorthstar (HGB-204) and HGB-205 studies, and the phase III Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies as of Mar 3, 2020.
The results showed that 89% of the evaluable patients (17/19) with transfusion-dependent β-thalassemia did not have a β0/β0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207
Data from exploratory analyses of HGB-207 showed improved markers of blood cell production and bone marrow function in patients who achieved transfusion independence.
Of the total, 85% of patients (11/13) with a β0/β0 genotype or IVS-I-110 mutation in HGB-212 had been transfusion-free for at least sevenmonths.
Shares of the company have decreased 27.2% year to date against the industry’s rise of 4.4%.
The company also announced new data from its ongoing phase I/II HGB-206 study of lentiGlobin gene therapy for adult and adolescent patients with sickle cell disease (SCD). The study showed a near-complete reduction of serious vaso-occlusive crises (VOCs) and acute chest syndrome (ACS).
In Group C of HGB-206, 25 patients were treated with LentiGlobin for SCD and had up to 24.8 months of follow-up.
The data showed 99.5% reduction in annualized rate of VOC and ACS in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up. At up to 24 months, there were no reports of serious VOC or ACS in Group C patients (n=18) with at least six months follow-up.
Group C patients with at least six months follow-up continued to produce consistent levels of gene therapy-derived anti-sickling hemoglobin (HbAT87Q) at up to 24 months, reducing levels of abnormal sickle hemoglobin (HbS)
Key markers of hemolysis approached near-normal levels in Group C patients, supporting the potential of LentiGlobin for SCD to modify the underlying pathophysiology of the disease.
The company is also developing its Lenti-D product candidate for cerebral adrenoleukodystrophy (CALD), a rare, hereditary neurological disorder, which can often be fatal. The FDA granted Breakthrough Therapy designation to Lenti-D for the treatment of patients with CALD, which should expedite the development and review of the therapy. Lenti-D also enjoys orphan drug status in the Unites States and Europe. It was also granted Rare Pediatric Disease designation by the FDA for the treatment of adrenoleukodystrophy.
Akcea’s loss per share estimates have narrowed from $2.07 to $1.37 for 2020 and from $2.46 per share to $1.85 for 2021 in the past 60 days.
Axcella’s loss per share estimates have narrowed from $1.14 to 79 cents for 2020 and from $3.30 per share to $3.03 for 2021 in the past 60 days.
Aytu’s loss per share estimates have narrowed from $1.26 to 12 cents for 2020 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Image: Bigstock
bluebird Reports New Data on Betibeglogene Autotemcel for TDT
bluebird Inc. (BLUE - Free Report) announced new data from ongoing phase III studies onits investigational betibeglogene autotemcel (formerly LentiGlobin for β-thalassemia gene therapy). The data showed that pediatric, adolescent and adult patients with a range of genotypes of transfusion-dependent β-thalassemia (TDT) achieved and maintained transfusion independence with hemoglobin (Hb) levels that are nearnormal.
TDT is a severe genetic disease caused by mutations in the β-globin gene that results in significantly reduced or absent adult hemoglobin (HbA).
A total of 60 pediatric, adolescent and adult patients across genotypes of TDT were treated with betibeglogenein the phase I/IINorthstar (HGB-204) and HGB-205 studies, and the phase III Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies as of Mar 3, 2020.
The results showed that 89% of the evaluable patients (17/19) with transfusion-dependent β-thalassemia did not have a β0/β0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207
Data from exploratory analyses of HGB-207 showed improved markers of blood cell production and bone marrow function in patients who achieved transfusion independence.
Of the total, 85% of patients (11/13) with a β0/β0 genotype or IVS-I-110 mutation in HGB-212 had been transfusion-free for at least sevenmonths.
Shares of the company have decreased 27.2% year to date against the industry’s rise of 4.4%.
The company also announced new data from its ongoing phase I/II HGB-206 study of lentiGlobin gene therapy for adult and adolescent patients with sickle cell disease (SCD). The study showed a near-complete reduction of serious vaso-occlusive crises (VOCs) and acute chest syndrome (ACS).
In Group C of HGB-206, 25 patients were treated with LentiGlobin for SCD and had up to 24.8 months of follow-up.
The data showed 99.5% reduction in annualized rate of VOC and ACS in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up. At up to 24 months, there were no reports of serious VOC or ACS in Group C patients (n=18) with at least six months follow-up.
Group C patients with at least six months follow-up continued to produce consistent levels of gene therapy-derived anti-sickling hemoglobin (HbAT87Q) at up to 24 months, reducing levels of abnormal sickle hemoglobin (HbS)
Key markers of hemolysis approached near-normal levels in Group C patients, supporting the potential of LentiGlobin for SCD to modify the underlying pathophysiology of the disease.
The company is also developing its Lenti-D product candidate for cerebral adrenoleukodystrophy (CALD), a rare, hereditary neurological disorder, which can often be fatal. The FDA granted Breakthrough Therapy designation to Lenti-D for the treatment of patients with CALD, which should expedite the development and review of the therapy. Lenti-D also enjoys orphan drug status in the Unites States and Europe. It was also granted Rare Pediatric Disease designation by the FDA for the treatment of adrenoleukodystrophy.
bluebird bio, Inc. Price
bluebird bio, Inc. price | bluebird bio, Inc. Quote
Zacks Rank and Other Stocks to Consider
bluebird currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are AkceaTherapeutics Inc. , Axcella Health Inc. and Aytu BioScience Inc. (AYTU - Free Report) , all carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Akcea’s loss per share estimates have narrowed from $2.07 to $1.37 for 2020 and from $2.46 per share to $1.85 for 2021 in the past 60 days.
Axcella’s loss per share estimates have narrowed from $1.14 to 79 cents for 2020 and from $3.30 per share to $3.03 for 2021 in the past 60 days.
Aytu’s loss per share estimates have narrowed from $1.26 to 12 cents for 2020 in the past 60 days.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2021.
Click here for the 6 trades >>